Abstract:Aim: To develop a combined population pharmacokinetic model (PPK) to assess the magnitude and variability of exposure to both clozapine and its primary metabolite norclozapine in Chinese patients with refractory schizophrenia via sparse sampling with a focus on the effects of covariates on the pharmacokinetic parameters. Methods: Relevant patient concentration data ( eg , demographic data, medication history, dosage regimen, time of last dose, sampling time, concentrations of clozapine and norclozapine, etc ) were collected using a standardized data collection form. The demographic characteristics of the patients, including sex, age, weight, body surface area, smoking status, and information on concomitant medications as well as biochemical and hematological test results were recorded. Persons who had smoked 5 or more cigarettes per day within the last week were defined as smokers. The concentrations of clozapine and norclozapine were measured using a HPLC system equipped with a UV detector. PPK analysis was performed using NONMEM. Age, weight, sex, and smoking status were evaluated as main covariates. The model was internally validated using normalized prediction distribution errors. Results: A total of 809 clozapine concentration data sets and 808 norclozapine concentration data sets from 162 inpatients (74 males, 88 females) at multiple mental health sites in China were included. The one-compartment pharmacokinetic model with mixture error could best describe the concentration-time profiles of clozapine and norclozapine. The population-predicted clearance of clozapine and norclozapine in female nonsmokers were 21.9 and 32.7 L/h, respectively. The population-predicted volumes of distribution for clozapine and norclozapine were 526 and 624 L, respectively. Smoking was significantly associated with increases in the clearance (clozapine by 45%; norclozapine by 54.3%). The clearance was significantly greater in males than in females (clozapine by 20.8%; norclozapine by 24.2%). The clearance of clozapine and norclozapine did not differ significantly between Chinese patients and American patients. Conclusion: Smoking and male were significantly associated with a lower exposure to clozapine and norclozapine due to higher clearance. This model can be used in individualized drug dosing and therapeutic drug monitoring.

Effect of Clonazepam Co-Administered with Clozapine on the Serum Clozapine and Norclozapine Concentration of Patients with Schizophrenia: A Retrospective Survey.

Effect of clonazepam co-administered with clozapine on the serum clozapine and norclozapine concentraiton of paitents with schizophrenia：A Retrospecitve Survey

Gender, Age, Smoking Behaviour And Plasma Clozapine Concentrations In 193 Chinese Inpatients With Schizophrenia

Relationship between plasma clozapine/N-desmethylclozapine and changes in basal forebrain-dorsolateral prefrontal cortex coupling in treatment-resistant schizophrenia

Clinical and pharmacological factors influencing serum clozapine and norclozapine levels

Pharmacokinetic Evaluation of Clozapine in Concomitant Use of Radix Rehmanniae, Fructus Schisandrae, Radix Bupleuri, or Fructus Gardeniae in Rats.

[Population Pharmacokinetics Research of Clozapine in Chinese Schizophrenic Patients].

A Case Report of Excessive Use of Clozapine Combined with Clonazepam.

Impact of patient-specific factors on clozapine metabolism in individuals with treatment-resistant schizophrenia or schizoaffective disorder

Population Pharmacokinetics of Clozapine and Its Primary Metabolite Norclozapine in Chinese Patients with Schizophrenia

Abstract P395: Clozapine Treatment for Schizophrenia May Cause Salt-sensitive Hypertension by Reducing the Expression of the Renal Dopamine D4 Receptor

The effect of smoking and sex on pharmacokinetics of clozapine and norclozapine

Clozapine and desmethylclozapine: correlation with neutrophils and leucocytes counting in Mexican patients with schizophrenia

Evaluation of major adverse events of clozapine based on accordance to an international titration guideline

Effect of fluvoxamine augmentation and smoking on clozapine serum concentrations

Differing Prevalence and Correlates of Metabolic Syndromes Between Chlorpromazine and Clozapine: A 10-year Retrospective Study of a Male Chinese Cohort

Effect of Organic Anion Transporting Polypeptide 1B1 on Plasma Concentration Dynamics of Clozapine in Patients with Treatment-Resistant Schizophrenia

The relationship of cardiovascular disease risk, clozapine antipsychotic use and cognitive function in a large Chinese schizophrenia cohort

Impact of clozapine monotherapy on gut microbiota and metabolism in people with schizophrenia

Absolute and Dose-Adjusted Serum Concentrations of Clozapine in Patients Switching vs. Maintaining Treatment: An Observational Study of 1979 Patients

Interindividual Variation In Relative Cyp1a2/3a4 Phenotype Influences Susceptibility Of Clozapine Oxidation To Cytochrome P450-Specific Inhibition In Human Hepatic Microsomes